|
|
Article: NewCo News: Arete Completes $51M Round For New Hypertension Class.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Arete Therapeutics Inc. added $35 million to its Series A financing round, bringing to $51 million the total the company has raised for its new class of drugs targeting hypertension and other conditions.
The Hayward, Calif., company was founded on the use of soluble epoxide hydrolase (s-EH) as an enzyme target for treatment of hypertension and inflammation. S-EH plays a role in a new, third pathway of arachidonic acid metabolism - epoxygenases; the other two, well-validated pathways are cyclooxygenases and lipoxygenases.
Small-molecule s-EH inhibitors under development were described as "hypertension-plus" by Dinesh Patel, president ...